

**PRODUCT INFORMATION**

<b>Target</b>	MAPT
<b>Synonyms</b>	TAU; MSTD; PPND; DDPAC; MAPTL; MTBT1; MTBT2; tau-40; FTDP-17; PPP1R103; Tau-PHF6
<b>Description</b>	Recombinant human MAPT Protein with N-terminal 6×His tag
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	P10636
<b>Expression Host</b>	HEK293
<b>Tag</b>	N-6×His tag
<b>Molecular Characterization</b>	6×His tag MAPT(Ala2-Leu758)
<b>Molecular Weight</b>	The protein has a predicted molecular mass of 79.6 kDa after removal of the signal peptide. The apparent molecular mass of His-MAPT is approximately 100-250 kDa due to glycosylation.
<b>Purity</b>	The purity of the protein is greater than 85% as determined by SDS-PAGE and Coomassie blue staining.
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Storage &amp; Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]
<b>Usage</b>	Research use only






Figure 1. Human MAPT Protein, His Tag on SDS-PAGE under reducing condition.

DIMABIO CONFIDENTIAL

